Alnylam begins ALN-AAT’s Phase I / II trial for alpha-1 liver disease
Alnylam Pharmaceuticals has started the Phase I / II clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) to treat AAT deficiency-associated liver disease (alpha-1 liver disea…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Alpha-1 Antitrypsin Deficiency | Clinical Trials | Liver | Liver Disease | Pharmaceuticals | Urology & Nephrology